Right Job, Wrong Tool: A Commentary on Designing Clinical Trials for Ebola Virus Disease

American Journal of Bioethics

Volumn 15, Issue 4, 2015, Pages 33-36

  Nelson, Robert M ^a   Roth Cline, Michelle ^a   Prohaska, Kevin ^a   Cox, Edward ^a   Borio, Luciana ^a   Temple, Robert ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VIRUS;

CLINICAL TRIAL (TOPIC); ETHICS; HEMORRHAGIC FEVER, EBOLA; HUMAN; HUMAN EXPERIMENT; METHODOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HEMORRHAGIC FEVER, EBOLA; HUMANS; RESEARCH DESIGN; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 84927588597     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2015.1010018     Document Type: Note

References (10)

1. Adebamowo, C., O. Bah-Sow, and F. Binka, et al. 2014. Randomised controlled trials for Ebola: Practical and ethical issues. Lancet. 384(9952), 1423–1424. Available at: http://dx.doi.org/10.1016/S0140-6736(14)61734-7
2. Ansumana, R., K. H. Jacobsen, and M. Idris, et al. 2014. Ebola in Freetown area, Sierra Leone—A case study of 581 patients. New England Journal of Medicine 24: 24.
3. Caplan, A. L., C. Plunkett, and B. Levin. 2015. Selecting the right tool for the job. American Journal of Bioethics 15(4): 4–10.
4. Cox, E., L. Borio, and R. Temple. 2014. Evaluating Ebola therapies—The case for RCTs. New England Journal Medicine 371(25): 2350–2351. http://dx.doi.org/10.1056/NEJMp1414145
5. Dudley, M. E., C. A. Gross, and R. P. Somerville, et al. 2013. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology 31(17): 2152–2159. Available at: http://dx.doi.org/10.1200/JCO.2012.46.6441
6. Gordon, P. H., Y. K. Cheung, and B. Levin, et al. 2008. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis 9(4): 212–222. Available at: http://dx.doi.org/10.1080/17482960802195632
7. Hay, M., D. W. Thomas, J. L. Craighead, C. Economides, and J. Rosenthal. 2014. Clinical development success rates for investigational drugs. Nature Biotechnology 32(1): 40–51. Available at: http://dx.doi.org/10.1038/nbt.2786
8. McNeil, D. G., Jr. 2015. Ebola doctors are divided on IV therapy in Africa. New York Times, January 1. Available at: http://www.nytimes.com/2015/01/02/health/ebola-doctors-are-divided-on-iv-therapy-in-africa.html
9. World Health Organization. 2014. Ethical issues related to study design for trials on therapeutics for Ebola virus disease. WHO Ethics Working Group Meeting, 20–21 October. Summary of discussion. Geneva, Switzerland: WHO.
10. Xu, B., Z. Jiang, and S. B. Kim, et al. 2011. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: A phase II randomized selection trial. Breast Cancer 18(3): 203–212. Available at: http://dx.doi.org/10.1007/s12282-011-0260-y